Azurity Pharmaceuticals Inc has acquired Arbor Pharmaceuticals Inc, marketers of the restless legs syndrome drug Horizant (gabapentin enacarbil).
With this acquisition, Arbor is now a wholly-owned subsidiary of Azurity. The two companies will begin to integrate their operations over the coming months and will operate as Azurity post-integration.
When Azurity announced the planned acquisition in August 2021, Amit Patel, chairman and CEO of Azurity, said in a release, “On behalf of the Azurity and Arbor teams, I am delighted to announce this agreement and the potential it brings to our combined company. The combination of the two companies, each steeped in rich legacies, will create a one-of-a-kind company leveraging increased scale and diversification, a breadth of dosage forms, integrated capabilities, and expanded market presence to better serve our patients’ needs.”
Ed Schutter, CEO of Arbor, said in a release, “Arbor is excited to be joining forces with Azurity to further our goal of bringing innovative products to the market that improve patients’ lives. I am proud of the business that our team has built over the last ten years and am confident that the combined entity will enhance our success and provide more treatment options for patients.”